Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00983346 · ClinicalTrials.gov registry record · Phase 2
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
A Phase 2 study, sponsored by University of Utah.
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT00983346: Clinical Trial Phase 2 study, sponsored by University of Utah.
NCT00983346 is a Phase 2 study that was terminated before completion, run by University of Utah. The registered enrollment target is 17 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00983346, a Phase 2 study, was terminated before completion, sponsored by University of Utah.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
OBJECTIVES * Primary: To evaluate the bone anabolic effect of bortezomib in patients with smoldering myeloma. * Secondary: To evaluate the effect of bortezomib on the natural history of smoldering myeloma.
Primary Outcome
The primary endpoint is the change in bone Alkaline Phosphatase at baseline and 6 weeks.
Interventions
- DRUG Bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2009-10 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
Why NCT00983346 stopped before completion
NCT00983346 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which Bortezomib is the first listed.
NCT00983346 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00983346 about?
NCT00983346 is a clinical study titled "Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients". OBJECTIVES * Primary: To evaluate the bone anabolic effect of bortezomib in patients with smoldering myeloma. * Secondary: To evaluate the effect of bortezomib on the natural history of smoldering myeloma.
What is the current status of trial NCT00983346?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2009-10. Estimated completion is 2014-09.
What interventions are being tested in trial NCT00983346?
The interventions under investigation include: Bortezomib (DRUG).
Who is sponsoring clinical trial NCT00983346?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00983346's enrollment target sits among peer trials
17 1903rd of 2000 higher than 93 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia